Comparison of the effect of tofacitinib and TNF inhibitor in ulcerative colitis

Comparison of the effect of tofacitinib and TNF inhibitor, in patients with ulcerative colitis resistant to mesalazine

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190717044255N8

Enrollment

Registered

2024-09-14

Start date

2024-09-20

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis. Ulcerative colitis

Interventions

Intervention 1: First intervention group: In this group, 49 patients will receive injectable adalimumab (Sinagen-Iran) every two weeks. In this way, the first dose will be 160 mg, the second dose will

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with ulcerative colitis resistant to mesalazine

Exclusion criteria

Exclusion criteria: History of allergy to studied drugs Presence of active infection History of blood malignancies History of other autoimmune diseases

Design outcomes

Primary

Measure	Time frame
Fecal calprotectin. Timepoint: Study start time and 6 months after. Method of measurement: Stool exam laboratory kit.;Clinical and endoscopic response of the patient. Timepoint: Stool exam laboratory kit. Method of measurement: Mayo score parameter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMona Reyhani

Arak University of Medical Sciences

drreyhani96@gmail.com+98 86 3836 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026